1 in 6 breast cancer cases is classified as triple negative (TNBC)? This challenging subtype lacks effective therapeutic targets and leaves those affected with limited options and a dismal prognosis when metastatic. 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲. 𝗘𝗨 𝗶𝘀 𝗼𝗳𝗳𝗲𝗿𝗶𝗻𝗴 𝗵𝗼𝗽𝗲.

RT @Accelerate_Eu: 🚀 Accelerate. EU Program Kick-Off! 🚀 We were happy to bring together 17 leading European institutions and companies fro…

Let's take a moment to celebrate Jérôme Harray remarkable dedication and leadership in making the Accelerate. EU project a reality! Thank you for the countless hours and unwavering vision you’ve invested to make this project possible.

🚀 Accelerate. EU Program Kick-Off! 🚀 We were happy to bring together 17 leading European institutions and companies from 9 countries for a highly constructive kick-off meeting of the Accelerate. EU program.  #AccelerateEU #At211 #astatine211 #CancerCare #Radiotheranostics

We pioneer the development of novel radiotheranostic pairs featuring the alpha-emitting isotope #astatine-211 to target aggressive cancers like pancreatic, breast, and brain #cancer.

We aim to ensure access to #211At across Europe and aligning research efforts, it will explore co-clinical approaches, where clinical studies run in parallel with preclinical studies, enhancing the ability to identify patients who are most likely to benefit from #alphatherapy.

The Accelerate .EU collaboration brings together 17 leading European institutions and companies across 9 countries, blending academic expertise with industrial innovation. The project is coordinated by @JulesBordet & @IBA_RadioPharma

🚀 #AccelerateEU has been granted EUR 16 million by the European Commission to establish strategic EU autonomy in #AlphaTherapies for cancer. It will focus on #Astatine211, expanding access to cutting-edge cancer treatments across Europe #CancerCare #HealthcareInnovation #211At